Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5C | P41229 | 3/20 | 0.48 |
| ▸ | KDM5B | Q9UGL1 | 3/20 | 0.48 |
| ▸ | KDM4A | O75164 | 2/20 | 0.48 |
| ▸ | KDM4B | O94953 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | HRH2 | P25021 | 1/20 | 0.41 |
| ▸ | KDM6B | O15054 | 1/20 | 0.41 |
| ▸ | KDM5A | P29375 | 1/20 | 0.41 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28168475 | 0.87 | SIGMAR1 (0.57) | SIGMAR1MAPK1PKMSMN1; SMN2MCHR1 | |
| SCHEMBL15637624 | 0.85 | MCHR1 (0.46) | KDM5CKDM5BKDM4ASIGMAR1MCHR1 | |
| SCHEMBL15635975 | 0.80 | SIGMAR1 (0.58) | SIGMAR1MCHR1MEN1ALDH1A1KMT2A | |
| SCHEMBL15636850 | 0.80 | DRD4 (0.55) | KDM5CKDM5BKDM4AKDM4BSIGMAR1 | |
| SCHEMBL15636721 | 0.79 | SIGMAR1 (0.52) | KDM5CKDM5BKDM4AKDM4BSIGMAR1 | |
| SCHEMBL15637011 | 0.76 | KDM5B (0.77) | KDM5CKDM5BKDM4AKDM4BSMN1; SMN2 | |
| SCHEMBL20779104 | 0.75 | SIGMAR1 (0.43) | KDM5CKDM5BKDM4ASIGMAR1KDM4C | |
| SCHEMBL19574680 | 0.74 | TSHR (0.43) | KDM5CKDM5BKDM4AKDM4BSIGMAR1 | |
| SCHEMBL19676463 | 0.73 | CRHR1 (0.39) | KDM5CKDM5BKDM4AKDM4BPKM | |
| SCHEMBL17710855 | 0.72 | CXCR4 (0.60) | KDM5CKDM5BKDM4AKDM4BSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10221139-B2 | Inhibitors of histone demethylases | GILEAD SCIENCES, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-10221139-B2 | Inhibitors of histone demethylases | GILEAD SCIENCES, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-10189787-B2 | Inhibitors of histone demethylases | GILEAD SCIENCES, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-10189787-B2 | Inhibitors of histone demethylases | GILEAD SCIENCES, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| EP-3023415-B1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES INC (US) | 2017-12-06 | — | — | EP | disclosed |
| EP-3023415-B1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES INC (US) | 2017-12-06 | — | — | EP | disclosed |
| US-20170320827-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2017-11-09 | — | — | US | disclosed |
| US-20170320827-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2017-11-09 | — | — | US | disclosed |
| EP-3150582-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-3150582-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-2903968-B1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES INC (US) | 2016-12-07 | — | — | EP | disclosed |
| EP-2903968-B1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES INC (US) | 2016-12-07 | — | — | EP | disclosed |
| EP-3023415-A1 | INHIBITORS OF HISTONE DEMETHYLASES | Epitherapeutics ApS (DK) | 2016-05-25 | — | — | EP | disclosed |
| EP-3023415-A1 | INHIBITORS OF HISTONE DEMETHYLASES | Epitherapeutics ApS (DK) | 2016-05-25 | — | — | EP | disclosed |
| EP-2903968-A1 | INHIBITORS OF HISTONE DEMETHYLASES | Epitherapeutics ApS (DK) | 2015-08-12 | — | — | EP | disclosed |
| US-20150203453-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2015-07-23 | — | — | US | disclosed |
| US-20150203453-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2015-07-23 | — | — | US | disclosed |
| US-20140371195-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2014-12-18 | — | — | US | disclosed |
| US-20140371195-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2014-12-18 | — | — | US | disclosed |
| WO-2014053491-A1 | INHIBITORS OF HISTONE DEMETHYLASES | EPITHERAPEUTICS APS (DK) | 2014-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10189787-B2 | Inhibitors of histone demethylases | EHMT1, KDM1B, EHMT2 | KDM5C 31/4885KDM5B 34/4885KDM4A 19/4885 |
| US-20150203453-A1 | INHIBITORS OF HISTONE DEMETHYLASES | EHMT1, KDM1B, EHMT2 | KDM5C 31/4885KDM5B 34/4885KDM4A 21/4885 |
| US-20140371195-A1 | INHIBITORS OF HISTONE DEMETHYLASES | EHMT1, KDM1B, EHMT2 | KDM5C 31/4885KDM5B 34/4885KDM4A 19/4885 |
| US-20170320827-A1 | INHIBITORS OF HISTONE DEMETHYLASES | EHMT1, KDM1B, EHMT2 | KDM5C 31/4885KDM5B 34/4885KDM4A 19/4885 |
| US-10221139-B2 | Inhibitors of histone demethylases | EHMT1, KDM1B, EHMT2 | KDM5C 31/4885KDM5B 34/4885KDM4A 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.